JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Ahmed E.M. | |
| dc.contributor.author | Khalil N.A. | |
| dc.contributor.author | Taher A.T. | |
| dc.contributor.author | Refaey R.H. | |
| dc.contributor.author | Nissan Y.M. | |
| dc.contributor.other | Pharmaceutical Organic Chemistry Department | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | Cairo University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Pharmaceutical Organic Chemistry Department | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | October 6 University | |
| dc.contributor.other | Giza | |
| dc.contributor.other | Egypt; Pharmaceutical Chemistry Department | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | October University for Modern Sciences and Arts (MSA) | |
| dc.contributor.other | Giza | |
| dc.contributor.other | Egypt; Pharmaceutical Chemistry Department | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | Cairo University | |
| dc.contributor.other | Kasr Elini St. | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | 11562 | |
| dc.contributor.other | Egypt | |
| dc.date.accessioned | 2020-01-09T20:40:31Z | |
| dc.date.available | 2020-01-09T20:40:31Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 452068 | |
| dc.identifier.other | https://doi.org/10.1016/j.bioorg.2019.103272 | |
| dc.identifier.other | PubMed ID 31539742 | |
| dc.identifier.uri | https://t.ly/AXqNp | |
| dc.description | Scopus | |
| dc.description.abstract | Novel series of some triazolo[4,3-b]pyridazine derivatives were designed and synthesized. All the newly synthesized compounds were evaluated for their cytotoxic activity at 10?5 M concentration towards 60 cancer cell lines according to USA NCI protocol. Most of the synthesized compounds showed good activity against SR (leukemia) cell panel. The most active compounds, 2f and 4a were subjected for further evaluation at a five dose level screening and their efficacy for c-Met kinase inhibition was determined in vitro. Binding mode of these derivatives was explored via molecular docking. 2019 Elsevier Inc. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=25789&tip=sid&clean=0 | |
| dc.language.iso | English | en_US |
| dc.publisher | Academic Press Inc. | en_US |
| dc.relation.ispartofseries | Bioorganic Chemistry | |
| dc.relation.ispartofseries | 92 | |
| dc.subject | c-Met kinase | en_US |
| dc.subject | Cytotoxic activity | en_US |
| dc.subject | Pyridazines | en_US |
| dc.subject | Triazolopyridazines | en_US |
| dc.subject | cytotoxic agent | en_US |
| dc.subject | phosphotransferase inhibitor | en_US |
| dc.subject | scatter factor receptor | en_US |
| dc.subject | triazolopyridazine derivative | en_US |
| dc.subject | antineoplastic activity | en_US |
| dc.subject | Article | en_US |
| dc.subject | breast cancer | en_US |
| dc.subject | cancer inhibition | en_US |
| dc.subject | central nervous system cancer | en_US |
| dc.subject | colon cancer | en_US |
| dc.subject | controlled study | en_US |
| dc.subject | drug binding | en_US |
| dc.subject | drug efficacy | en_US |
| dc.subject | drug screening | en_US |
| dc.subject | drug synthesis | en_US |
| dc.subject | enzyme activity | en_US |
| dc.subject | enzyme inhibition | en_US |
| dc.subject | GI50 | en_US |
| dc.subject | human | en_US |
| dc.subject | human cell | en_US |
| dc.subject | IC50 | en_US |
| dc.subject | in vitro study | en_US |
| dc.subject | kidney cancer | en_US |
| dc.subject | leukemia | en_US |
| dc.subject | melanoma | en_US |
| dc.subject | molecular docking | en_US |
| dc.subject | non small cell lung cancer | en_US |
| dc.subject | ovary cancer | en_US |
| dc.subject | priority journal | en_US |
| dc.subject | prostate cancer | en_US |
| dc.subject | proton nuclear magnetic resonance | en_US |
| dc.subject | structure activity relation | en_US |
| dc.title | Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking | en_US |
| dc.type | Article | en_US |
| dcterms.isReferencedBy | Liu, X., Yao, W., Newton, R.C., Scherle, P.A., Targeting the c-MET signaling pathway for cancer therapy (2008) Exp. Opin. Invest. Drugs, 17 (7), pp. 997-1011; Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., Birchmeler, C., Scatter factor/hepatocyte growth factor is essential for liver development (1995) Nature, 373 (6516), p. 699; Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., Kitamura, N., Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor (1995) Nature, 373 (6516), p. 702; Kawaida, K., Matsumoto, K., Shimazu, H., Nakamura, T., Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice (1994) PNAS, 91 (10), pp. 4357-4361; Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., Matsuda, H., Nakamura, T., Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF (2000) J. Clin. Investig., 106 (12), pp. 1511-1519; Tsubouchi, H., Niitani, Y., Hirono, S., Nakayama, H., Gohda, E., Arakaki, N., Sakiyama, O., Kawakami, S., Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay (1991) Hepatology, 13 (1), pp. 1-5; Birchmeier, C., Birchmeier, W., Gherardi, E., Vande Woude, G.F., Met, metastasis, motility and more (2003) Nat. Rev. Mol. Cell Biol., 4, p. 915; Maroun, C.R., Rowlands, T., The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance (2014) Pharmacol. Ther., 142 (3), pp. 316-338; Comoglio, P.M., Giordano, S., Trusolino, L., Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008) Nat. Rev. Drug Discov., 7, p. 504; Sun, Z.-G., Yang, Y.-A., Zhang, Z.-G., Zhu, H.-L., Optimization techniques for novel c-Met kinase inhibitors (2019) Exp. Opin. Drug Discov., 14 (1), pp. 59-69; Malik, S.M., Maher, V.E., Bijwaard, K.E., Becker, R.L., Zhang, L., Tang, S.W., Song, P., Pazdur, R., U.S. Food and Drug Administration Approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive (2014) Clin. Canc. Res., 20 (8), pp. 2029-2034; Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Bruix, J., Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study (2018) Lancet Oncol., 19 (5), pp. 682-693; Traynor, K., Cabozantinib approved for advanced medullary thyroid cancer (2013) Am. J. Health Syst. Pharm., 70 (2), p. 88; Yau, T.C.C., Lencioni, R., Sukeepaisarnjaroen, W., Chao, Y., Yen, C.-J., Lausoontornsiri, W., Chen, P.-J., Bottaro, D.P., A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma (2017) Clin. Canc. Res. Off. J. Am. Assoc. Canc. Res., 23 (10), pp. 2405-2413; Albrecht, B.K., Harmange, J.-C., Bauer, D., Berry, L., Bode, C., Boezio, A.A., Chen, A., Fridrich, C., Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase (2008) J. Med. Chem., 51 (10), pp. 2879-2882; Boezio, A.A., Berry, L., Albrecht, B.K., Bauer, D., Bellon, S.F., Bode, C., Chen, A., Harmange, J.-C., Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors (2009) Bioorg. Med. Chem. Lett., 19 (22), pp. 6307-6312; Ryu, J.W., Han, S.-Y., Yun, J.I., Choi, S.-U., Jung, H., Ha, J.D., Cho, S.Y., Lee, J., Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors (2011) Bioorg. Med. Chem. Lett., 21 (23), pp. 7185-7188; Sattler, M., Hasina, R., Reddy, M.M., Gangadhar, T., Salgia, R., The role of the c-Met pathway in lung cancer and the potential for targeted therapy (2011) Therap. Adv. Med. Oncol., 3 (4), pp. 171-184; Underiner, T.L., Herbertz, T., Miknyoczki, S.J., Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates, anti-cancer agents in medicinal (2010) Chem.- Anti-Cancer Age., 10 (1), pp. 7-27; Buchanan, S.G., Hendle, J., Lee, P.S., Smith, C.R., Bounaud, P.-Y., Jessen, K.A., Tang, C.M., Reich, S.H., SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo (2009) Mol. Cancer Ther., 8 (12), pp. 3181-3190; Abouzid, K.A.M., Khalil, N.A., Ahmed, E.M., Esmat, A., Al-Abd, A.M., Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives (2012) Med. Chem. Res., 21 (11), pp. 3581-3590; Abouzid, K.A.M., Khalil, N.A., Ahmed, E.M., Mohamed, K.O., 3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity (2013) Arch. Pharm. Res., 36 (1), pp. 41-50; Rostom, S.A., Synthesis and in vitro antitumor evaluation of some indeno [1, 2-c] pyrazol (in) es substituted with sulfonamide, sulfonylurea (-thiourea) pharmacophores, and some derived thiazole ring systems (2006) Bioorg. Med. Chem., 14 (19), pp. 6475-6485; Furlan, A., Colombo, F., Kover, A., Issaly, N., Tintori, C., Angeli, L., Leroux, V., Maina, F., Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling (2012) Eur. J. Med. Chem., 47, pp. 239-254; Rasmussen, J.T., Petiwala, S.M., Johnson, J.J., Kohl, A.M., Syed, D.N., Mukhtar, H., Siddiqui, I.A., Adhami, V.M., ?-Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth (2011) Carcinogenesis, 33 (2), pp. 413-419; Porter, J., Small molecule c-Met kinase inhibitors: a review of recent patents (2010) Exp. Opin. Ther. Pat., 20 (2), pp. 159-177; Gherardi, E., Birchmeier, W., Birchmeier, C., Woude, G.V., Targeting MET in cancer: rationale and progress (2012) Nat. Rev. Cancer, 12 (2), p. 89; Boyd, M.R., Paull, K.D., Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen (1995) Drug Dev. Res., 34 (2), pp. 91-109; Grever, M.R., Schepartz, S.A., Chabner, B.A., The National Cancer Institute: cancer drug discovery and development program (1992) Semin. Oncol., 19 (6), pp. 622-638; Monks, A., Vaigro-Wolff, A., Hose, C., Scudiero, D., Campbell, H., Langley, J., Gray-Goodrich, M., Shoemaker, R., Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines (1991) JNCI: J. Natl. Canc. Instit., 83 (11), pp. 757-766; Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Boyd, M.R., New colorimetric cytotoxicity assay for anticancer-drug screening (1990) JNCI: J. Natl. Cancer Instit., 82 (13), pp. 1107-1112; Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., Olson, A.J., AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility (2009) J. Comput. Chem., 30 (16), pp. 2785-2791; Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The protein data bank (2000) Nucl. Acids Res., 28 (1), pp. 235-242; Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimeraa visualization system for exploratory research and analysis (2004) J. Comput. Chem., 25 (13), pp. 1605-1612 | |
| dcterms.source | Scopus | |
| dc.identifier.doi | https://doi.org/10.1016/j.bioorg.2019.103272 | |
| dc.identifier.doi | PubMed ID 31539742 | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
